Select Page

Home / News / BioBlast® / Biosimilar Deals 2021

EXPLORE OUR

Biosimilars Deals 2021

Explore our interactive biosimilar news updates, collating tailored reports by brand, INN, originator/biosimilar applicant, litigation, region, or date. Alternatively, review our weekly BioBlast updates below.

Formycon/Klinge Partners with Actor in AU and Megalabs in LATAM for Biosimilar Aflibercept

On 16 October 2025, Formycon announced that Klinge Biopharma, the exclusive holder of the global commercialisation rights for Formycon’s FYB203, biosimilar to Regeneron/Bayer’s Eylea® (aflibercept), has entered exclusive licence agreements with Actor Pharmaceuticals and Uruguay-based Megalabs S.A. for the commercialisation of FYB203 in Australia and Latin America, respectively.

Under the agreements, Klinge is eligible to receive upfront and milestone payments and royalties on net sales.  Formycon will participate in all payment streams to Klinge, in the mid-single digit to low-double digit percentage range and will receive additional payments for organising the commercial market supply on behalf of Klinge.

According to Formycon, a regulatory application for FYB203 has been submitted to the Australian Therapeutic Goods Administration (TGA), while Formycon is working closely with Megalabs to prepare marketing applications for Latin American countries.

The agreements follow semi-exclusive commercialisation agreements between Klinge and Horus Pharma (September 2025) and Klinge and Teva Pharmaceuticals (January 2025) for FYB203, covering major parts of Europe (excluding Italy) and Israel.  Horus will market the product as Baiama®, while Teva will market it as Ahzantive®.  In June 2025, Klinge entered an exclusive licence agreement with Valorum for commercialisation of FYB203 in the US and Canada.

FYB203/Ahzantive® was approved by the FDA in June 2024 and is set to launch in the US in Q4/2026 following settlement of BPCIA litigation between Formycon and Regeneron in October 2025.  The biosimilar may launch in the UK in November 2025, following a February 2025 approval by the MHRA and a failed UK preliminary injunction bid by Regeneron in October 2025 (which is subject to any appeal).  The situation is less clear in Europe, where, on 25 September 2025, the Munich Regional Court granted Regeneron and Bayer a cross-border preliminary injunction (PI) preventing Formycon from launching FYB203 in a number of European countries, including Germany.  FYB203 received European marketing approval in January 2025 as Baiama® and Ahzantive®.

PiPCast™ | Australian Preliminary Injunction Trends in Life Sciences Patent Litigation

Pearce IP’s CEO, Naomi Pearce, discusses trends in preliminary injunctions in Australian life sciences patent cases with Head of Litigation (Australia), Helen Macpherson, following the recent Federal Court refusal of Regeneron’s and Bayer’s patent PI application against Sandoz relating to their AUD$500M/year blockbuster aflibercept (Eylea®).

Pearce IP BioBlast® for the week ending 10 October 2025

Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®.  Significant biosimilar activities for the week ending 10 October 2025 are set out below:


Aflibercept

10 October 2025 | US | Celltrion’s Biosimilar Aflibercept Sixth Approved in US

On 10 October 2025, Celltrion announced that the FDA has approved Eydenzelt® (CT-P42), biosimilar to Regeneron/Bayer’s Eylea®… Read more here.

9 October 2025 | NZ | Sandoz’s Afqlir® First Aflibercept Biosimilar Approved in NZ

On 9 October 2025, New Zealand’s Medsafe approved Sandoz’s Afqlir®, biosimilar to Regeneron/Bayer’s Eylea® (aflibercept 2mg)… Read more here.

8 October 2025 | UK | Regeneron & Bayer Fail in Bid to Prevent UK Launch of Aflibercept Biosimilars by Samsung Bioepis and Formycon/Klinge

On 8 October 2025, judgment was published in patent infringement proceedings brought by Regeneron/Bayer in the UK seeking… Read more here.


Golimumab

9 October 2025 | CA | Bio-Thera and Intas Expand Biosimilar Golimumab Partnership to Canada

On 9 October 2025, Bio-Thera Solutions announced that it has entered an exclusive commercialisation and licence agreement for Canada Read more here.

7 October 2025 | US | New Indication Alert: J&J’s Simponi® (Golimumab) FDA-Approved for Paediatric UC

On 7 October 2025, Johnson & Johnson announced that the FDA has approved Simponi® (golimumab) for treating children living with moderately to severely… Read more here.


Nivolumab

12 October 2025 | IN | India’s SEC Instructs Enzene to Revise Ph III Trial Protocol for Biosimilar Nivolumab

On 12 October 2025, Medical Dialogues reported that India’s Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation… Read more here.


Omalizumab

6 October 2025 | EU | EMA Accepts Alvotech’s Marketing Authorisation Application for Biosimilar Omalizumab

On 6 October 2025, Alvotech announced that the European Medicines Agency (EMA) has accepted its marketing authorisation application (MAA) for AVT23… Read more here.


Pembrolizumab

7 October 2025 | US | PTAB Invalidates 4 of Johns Hopkins’ US Pembrolizumab Patents in MSD IPRs

Between 18 and 23 September 2025, the US Patent Trial and Appeal Board (PTAB) issued final decisions invalidating Johns Hopkins University’s… Read more here.


Ustekinumab

9 October 2025 | NZ | Celltrion’s Steqeyma® First Ustekinumab Biosimilar Approved in NZ

On 9 October 2025, New Zealand’s Medsafe approved Celltrion’s Steqeyma®, biosimilar to Janssen’s Stelara® (ustekinumab), in vial and pre-filled syringe… Read more here.


BioPharma Deals

6 October 2025 | JP | Japan Grows Domestic Biosimilar Supply System

On 6 October 2025, Alfresa Holdings announced that it has entered into agreements with two other Japanese companies, Kidswell Bio Corporation and Chiome Bioscience… Read more here.


 

 

About Pearce IP

Pearce IP is a specialist firm offering intellectual property specialist lawyers and attorneys with a focus on the life sciences industries.  Pearce IP and its leaders are ranked in every notable legal directory for legal, patent and trade mark excellence, including: Chambers & Partners, Legal 500, IAM Patent 1000, IAM Strategy 300, MIP IP Stars, Doyles Guide, WTR 1000, Best Lawyers, WIPR Leaders, 5 Star IP Lawyers, among others.

In 2025, Pearce IP was recognised by Australasian Lawyer and New Zealand Lawyer’s 5 Star Employer of Choice, and is the “Standout Winner” for inclusion and culture for firms with less than 100 employees. Pearce IP was awarded “IP Team of the Year” by Lawyers Weekly at the 2021 Australian Law Awards. Pearce IP is recognised by Managing IP as the only leading ANZ IP firm with a female founder, and is certified by WEConnect International as women owned.

 

Naomi Pearce

Naomi Pearce

CEO, Executive Lawyer (AU, NZ), Patent Attorney (AU, NZ) & Trade Mark Attorney (AU)

Naomi is the founder of Pearce IP, and is one of Australia’s leading IP practitioners.   Naomi is a market leading, strategic, commercially astute, patent lawyer, patent attorney and trade mark attorney, with over 25 years’ experience, and a background in molecular biology/biochemistry.  Ranked in virtually every notable legal directory, highly regarded by peers and clients, with a background in molecular biology, Naomi is renown for her successful and elegant IP/legal strategies.

Among other awards, Naomi is ranked in Chambers, IAM Patent 1000, IAM Strategy 300, is a MIP “Patent Star”, and is recognised as a WIPR Leader for patents and trade marks. Naomi is the 2023 Lawyers Weekly “IP Partner of the Year”, the 2022 Lexology client choice award recipient for Life Sciences, the 2022 Asia Pacific Women in Business Law “Patent Lawyer of the Year” and the 2021 Lawyers Weekly Women in Law SME “Partner of the Year”.  Naomi is the founder of Pearce IP, which commenced in 2017 and won 2021 “IP Team of the Year” at the Australian Law Awards.

Chantal Savage

Chantal Savage

Special Counsel, Lawyer

Chantal is an intellectual property disputes lawyer with experience advising across the spectrum of IP rights, including patents, trade marks, copyright, plant breeder’s rights and trade secrets/confidential information. Recognised as a Rising Star in IP by the Legal 500 Asia Pacific (2021-2024), Chantal has previously worked for international and top tier law firms in Australia and the United Kingdom and now at Pearce IP.

With a science degree specialising in molecular biology and biochemistry, Chantal’s practice focuses particularly on complex, high-value, multi-jurisdictional patent infringement and revocation proceedings for clients in the life sciences sectors.

Nathan Kan

Nathan Kan

Lawyer

Nathan is a lawyer specialising in life sciences, providing legal advice and litigation support across intellectual property and commercial disputes. He is passionate about the intersection of law and science, and during his time with the Science and Technology Law Association at the University of Melbourne, he helped lead events, workshops and publications across STEM fields including life sciences, AI and digital transformation.

 

India’s SEC Approves Phase I/III Trial for Reliance Life Science’s Biosimilar Nivolumab

On 14 October 2025, Medical Dialogues reported that India’s Subject Expert Committee (SEC) of the Central Drugs Standard Control Organization (CDSCO) has approved Reliance Life Sciences’ Phase I/III clinical trial for its biosimilar nivolumab (R-TPR-067 or RLS-Nivolumab).

The trial is intended to establish comparability in efficacy, safety, pharmacokinetics, and immunogenicity between R-TPR-067 and the reference product, BMS’ Opdivo® (sold as Opdyta® in India), administered intravenously in patients previously treated for locally advanced or metastatic non-small cell lung cancer.

This puts Reliance ahead of Enzene in their respective efforts to have a nivolumab biosimilar approved in India, as the SEC requested Enzene to revise its Phase III trial protocol.  However, both companies lag behind Zydus, which had its nivolumab biosimilar approved in India in July 2024, but which has since faced injunction proceedings before the Delhi High Court.

Amgen, Sandoz and Xbrane/Intas also have nivolumab biosimilars in development.

Regeneron to Submit Additional Manufacturer to FDA for Eylea HD® Due to Catalent FDA Action

On 13 October 2025, Regeneron announced that it has been notified by Catalent Indiana, LLC, which was acquired by Novo Nordisk and is the manufacturer filler included in the supplemental BLA for Regeneron’s high dose (8mg) formulation of Eylea® (aflibercept), that Catalent received an “official action indicated” classification from the FDA on 9 October 2025.  This classification indicates that the facility is in an “unacceptable state of compliance” after an FDA inspection.

Regeneron’s Eylea HD® (aflibercept, 8mg) is already approved in the US in a vial form for nAMD, DME and diabetic retinopathy (August 2023).  However, Regeneron has filed an sBLA in the US for the use of Eylea HD® to treat macular oedema following retinal vein occlusion (RVO) and for an extension of the dosing schedule to include every 4-week dosing across approved indications.  Regeneron has also filed a US regulatory submission for Eylea HD® in a pre-filled syringe.

In August 2025, the FDA extended its target action date for these regulatory submissions (to Q4/2025) as a result of FDA observations based on an inspection at Novo Nordisk’s Catalent filling site.

According to Regeneron, while Catalent continues to work with the FDA to resolve the outstanding compliance issues, within the next 3 months, Regeneron is planning to submit an application to the FDA to include an additional manufacturing filler in the Eylea HD® BLA.

Eylea HD® (known as Eylea™ 8mg in Europe) was jointly developed by Bayer and Regeneron.  Regeneron holds the exclusive rights to both 2mg and 8mg Eylea® in the US, while Bayer holds those outside the US, where the companies equally share the profits from sales of the products.

Eylea® 8mg for intravitreal injection is approved for nAMD and DME including in the EU (January 2024), Japan (January 2024), UK (January 2024) and Australia (June 2024).  Eylea® 8mg pre-filled syringe (OcuClick) was approved in Europe (September 2024), Australia (October 2024) and Korea (August 2025).  In addition to the US application, Regeneron/Bayer have submitted marketing authorisation applications for Eylea® 8mg for the treatment of patients with macular oedema following RVO in Japan (May 2025) and Europe (April 2025).

Alvotech is developing AVT29, a biosimilar to Regeneron’s Eylea® 8mgTeva holds commercialisation rights for AVT29 (and AVT06, aflibercept 2mg) in the US.  In June 2024, Alvotech entered into an agreement with Advanz Pharma in relation to the commercialisation of AVT29 (and AVT06) in Europe.

India’s SEC Instructs Enzene to Revise Ph III Trial Protocol for Biosimilar Nivolumab

On 12 October 2025, Medical Dialogues reported that India’s Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO) has requested Alkem subsidiary, Enzene Biosciences, to revise its proposed Phase III clinical trial protocol for biosimilar nivolumab (injection 100mg/10mL vial).

According to the report, Enzene requested permission to conduct a multicentre, Phase III trial comparing its biosimilar nivolumab with BMS’ Opdivo® (nivolumab) in adults with recurrent locoregional or metastatic squamous cell carcinoma of the head and neck, progressing on or after platinum-based therapy.

The SEC recommended a number of modifications to the protocol, including narrowing the non-inferiority margin used for sample size calculation and adding provisions for reporting safety data from the initial 20% of enrolled subjects.  Enzene has been instructed to submit a revised protocol incorporating the changes recommended by the SEC.

At least one other nivolumab biosimilar has already received regulatory approval in India, with Zydus’ biosimilar approved in July 2024 for locally advanced or metastatic non-small cell lung cancer, and conditional approval for all other approved indications of BMS’ Opdivo®.  Amgen, Sandoz and Xbrane/Intas also have nivolumab biosimilars under development.

Celltrion’s Biosimilar Aflibercept Sixth Approved in US

On 10 October 2025, Celltrion announced that the FDA has approved Eydenzelt® (CT-P42), biosimilar to Regeneron/Bayer’s Eylea® (aflibercept 2mg), for treating nAMD, macular oedema following retinal vein occlusion, diabetic macular oedema and diabetic retinopathy.  The launch date for the product remains uncertain given pending BPCIA litigation brought by Regeneron against Celltrion regarding Eydenzelt®.

Eydenzelt® is the sixth aflibercept (2mg) biosimilar to be approved in the US following: Sandoz’s Enzeevu™ (August 2024), Amgen’s Pavblu™ (August 2024) Formycon/Klinge’s Ahzantive®/FYB203 (June 2024), Biocon’s Yesafili™ (May 2024) and Samsung Bioepis’ Opuviz™/SB15 (May 2024).

Amgen’s Pavblu® is the only aflibercept biosimilar to have launched in the US, in October 2024, following the Court of Appeals for the Federal Circuit’s denial of Regeneron’s application for an injunction against Amgen.  Regeneron has since commenced new BPCIA litigation against Amgen for Pavblu™ (June 2025), which remains pending.

Launches of other US-approved aflibercept biosimilars have been delayed by BPCIA litigation brought by Regeneron.  However, the following proceedings have now settled, with biosimilar launches scheduled for 2026:

Preliminary injunctions were granted, and remain in place, preventing US biosimilar aflibercept launches by Samsung Bioepis (14 June 2024, upheld on appeal on 29 January 2025) and Celltrion (June-July 2024, upheld on appeal on 5 March 2025).

Eydenzelt® was the fifth approved aflibercept biosimilar in Europe, in February 2025 (but has not yet launched), and received Korean approval in May 2024.  In Australia, Eydenzelt® was approved solely for myopic CNV on 31 March 2025.  However, in July 2025, Celltrion filed an application with the TGA to expand Eydenzelt®’s indications to all those of Eylea®.  Eydenzelt® will be considered for reimbursement at the November 2025 meeting of Australia’s Pharmaceutical Benefits Advisory Committee (PBAC).

Celltrion’s Steqeyma® First Ustekinumab Biosimilar Approved in NZ

On 9 October 2025, New Zealand’s Medsafe approved Celltrion’s Steqeyma®, biosimilar to Janssen’s Stelara® (ustekinumab), in vial and pre-filled syringe presentations, making Steqeyma® the first ustekinumab biosimilar approved in New Zealand.

Celltrion’s Steqeyma® has been approved and launched in a number of regions, including Korea (approved June 2024), Canada (approved July 2024, launched August 2024), the EU (approved September 2024, launched November 2024), the UK (approved September 2024, launched December 2024), Australia (approved September 2024, launched September 2025), the US (approved December 2024, launched March 2025), and Japan (approved March 2025, launched July 2025).

In August 2025, Steqeyma® became the first ustekinumab biosimilar to be listed on Australia’s Pharmaceutical Benefits Scheme (PBS).

Bio-Thera and Intas Expand Biosimilar Golimumab Partnership to Canada

On 9 October 2025, Bio-Thera Solutions announced that it has entered an exclusive commercialisation and licence agreement for Canada with Intas Pharmaceuticals in relation to BAT2506, biosimilar to J&J’s Simponi® (golimumab).

This expands the existing partnership between the companies in relation to commercialisation of BAT2506 in the US, under a February 2025 agreement.  Under that agreement, Intas’ subsidiary, Accord BioPharma, is responsible for commercialising BAT2506 in the US, while Bio-Thera retains responsibility for development, manufacturing and supply.  Bio-Thera receives an upfront payment of US$21 million and further development and commercial milestone payments of up to US$143.5 million.  The financial arrangements in relation to the Canadian expansion of the partnership have not been published.

Bio-Thera’s BLA for BAT2506 was accepted for review by the FDA in July 2025.  In February 2025, the MAA for BAT2506 was accepted for review in Europe, where the biosimilar is being commercialised by STADA under a May 2024 agreement with Bio-Thera.  Bio-Thera has also entered into commercialisation agreements for BAT2506 with SteinCares for Latin America (March 2024) and Dr Reddy’s for South East Asia (March 2025).

Sandoz’s Afqlir® First Aflibercept Biosimilar Approved in NZ

On 9 October 2025, New Zealand’s Medsafe approved Sandoz’s Afqlir®, biosimilar to Regeneron/Bayer’s Eylea® (aflibercept 2mg), in vial and pre-filled syringe presentations, making Afqlir® the first aflibercept biosimilar approved in New Zealand.

Sandoz’s aflibercept biosimilars have received approval in a number of jurisdictions, including the US (August 2024, as Enzeevu®), the EU (November 2024, as Afqlir®), and Australia (May 2025, as Afqlir® and Enzeevu®).  Afqlir® and Enzeevu® were the first aflibercept biosimilars to be considered and recommended for listing on Australia’s Pharmaceutical Benefits Scheme (PBS), with listing anticipated on 1 December 2025.

Aflibercept is currently the subject of patent infringement proceedings in Australia.  On 8 September 2025, the Federal Court of Australia published a judgment refusing to award Regeneron and Bayer an interlocutory injunction against Sandoz to prevent the launch of Sandoz’s Afqlir®.  Regeneron/Bayer filed an application for leave to appeal that decision on 17 September 2025.  Regeneron/Bayer are separately seeking preliminary discovery from Sandoz in relation to a second Regeneron aflibercept patent, AU2020397865, which is scheduled for hearing on 6 November 2025.

Actor Pharmaceuticals, which does not yet have an aflibercept biosimilar approved in Australia, filed revocation proceedings against Regeneron and Bayer in the Australian Federal Court on 5 August 2025, seeking to invalidate AU2012205599, with a first case management hearing in that matter currently scheduled for 6 November 2025.

Dutch Court Grants Injunction Preventing Netherlands Launch of Samsung Bioepis’ Biosimilar Aflibercept

On 9 October 2025, The Hague District Court published its decision in legal proceedings between Samsung Bioepis and Regeneron in relation to Regeneron’s Dutch equivalents of European patents EP 2 364 691 and EP 1 183 353, covering formulations of aflibercept.  The Court found that the patents were valid and that claim 6 of the ‘691 Patent (an independent claim to a specific lyophilizable formulation of a VEGF antagonist wherein the formulation can be reconstituted so it is suitable for intravitreal administration) was infringed by Samsung Bioepis’ Opuviz™.  As a result, the Court granted an injunction preventing Samsung Bioepis from infringing that claim in the Netherlands.  The Court denied Regeneron’s request for a cross-border injunction.

The decision of the Dutch Court follows recent decisions in Germany and the UK in relation to Regeneron’s aflibercept patents.  In September 2025, the Munich Regional Court granted Regeneron and Bayer a cross-border preliminary injunction preventing Formycon from launching its aflibercept biosimilar (FYB203) based on a finding of infringement by equivalence of the ‘691 patent.  In comparison, in the UK, the High Court determined that Formycon/Klinge’s and Samsung Bioepis’ aflibercept biosimilars did not infringe either the ‘691 patent or Regeneron’s EP (UK) 2 944 306 and that the ‘306 patent was invalid.

Samsung Bioepis’ Opuviz™ (SB15) was the third aflibercept biosimilar approved in Europe in November 2024.  Samsung Bioepis and Biogen entered into a commercialisation agreement for Opuviz™ (SB15) in November 2019 for US, Canada, Europe, Japan and Australia.  No aflibercept biosimilars have launched in Europe to date.

Pearce IP BioBlast® for the week ending 3 October 2025

Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®.  Significant biosimilar activities for the week ending 3 October 2025 are set out below:


Aflibercept

2 October 2025 | US | Formycon/Klinge/Valorum Set for Q4/2026 Biosimilar Aflibercept US Launch Following Regeneron Settlement

On 2 October 2025, Formycon announced that it and its licence partners, Klinge Biopharma and Valorum Biologics, have entered a settlement and licence agreement with Regeneron… Read more here.


Bevacizumab

29 September 2025 | US | Outlook Therapeutics to Resubmit Ophthalmic Bevacizumab BLA to FDA Before End 2025

On 29 September 2025, Outlook Therapeutics announced that it has completed a Type A Meeting with the FDA to discuss the August 2025 complete response letter (CRL)… Read more here.


Denosumab

1 October 2025 | US | Biocon Launches Denosumab Biosimilars in US Following Amgen Settlement

On 1 October 2025, Biocon announced that it has entered into a settlement and licence agreement with Amgen that resolves pending BPCIA patent litigation and permits… Read more here.

29 September 2025 | US | Richter/Hikma’s Biosimilar Denosumab Seventh Approved in US

On 29 September 2025, Gedeon Richter and Hikma Pharmaceuticals announced they have secured FDA approval for Enoby™ (RGP-14-P) and Xtrenbo™… Read more here.

29 September 2025 | US | US Reimbursement Boost for Fresenius’ Biosimilar Denosumab

On 29 September 2025, Fresenius Kabi announced that the US Centers for Medicare and Medicaid Services (CMS) assigned a permanent billing code for… Read more here.

5 September 2025 | US | Samsung Bioepis & Amgen Settle BPCIA Denosumab Litigation

On 5 September 2025, consent orders were made by the US District Court for the District of New Jersey recording that Samsung Bioepis and Amgen… Read more here.


Etanercept

1 October 2025 | AU | Sandoz’s Biosimilar Etanercept PBS-Listed

On 1 October 2025, Sandoz’s Erelzi®, biosimilar to Amgen/Pfizer’s Enbrel® (etanercept), was listed on Australia’s Pharmaceutical Benefits Scheme… Read more here.


Guselkumab 

29 September 2025 | US | New Indication Alert: FDA Extends J&J’s Guselkumab to PsO and PsA in Children

On 29 September 2025, Johnson & Johnson announced that the US FDA has approved an indication extension for Tremfya® (guselkumab) for the treatment of… Read more here.


Nivolumab, Ipilimumab

1 October 2025 | US | PTAB Grants Amgen Adverse Judgment Against BMS’ Disclaimed Nivolumab/Ipilimumab Patent

On 1 October 2025, the US Patent Trial and Appeal Board (PTAB) issued its decision in the inter partes review (IPR), filed by Amgen in February 2025 and instituted in July 2025… Read more here.


Secukinumab

29 September 2025 | US | Novartis to Launch US Direct Sales Platform for Secukinumab

On 29 September 2025, Novartis announced that it plans to launch a US direct-to-patient (DTP) platform for Cosentyx® (secukinumab) from 1 November 2025… Read more here.


Tocilizumab

3 October 2025 | US | Celltrion Launches IV Tocilizumab Biosimilar in US

On 3 October 2025, Celltrion announced that it has launched its intravenous formulation of Avtozma®/CT-P47, biosimilar to Roche’s Actemra® (tocilizumab), in the United States… Read more here.


Ustekinumab

3 October 2025 | AU | Samsung Bioepis Successfully Opposes Grant of Janssen’s AU Ustekinumab Patent Application

On 3 October 2025, IP Australia delivered its decision in Samsung Bioepis’ opposition to the grant of Janssen’s AU2019346134 relating to a method of treating ulcerative colitis… Read more here.

3 October 2025 | CSPC Pharmaceutical’s Biosimilar Ustekinumab Ph 3 Results

On 3 October 2025, Pharmacy Times reported that CSPC Pharmaceutical Group’s SYSA1902 has been shown in a phase 3 study to be clinically equivalent to its reference product… Read more here.


BioPharma Deals

6 October 2025 | MENA | Celltrion & Hikma Expand MENA Partnership to Include 6 Additional Biosimilars

On 6 October 2025, Hikma Pharmaceuticals and Celltrion Inc, announced that they have entered exclusive licensing agreements for 6 biosimilars… Read more here.

29 September 2025 | Genmab to Acquire Merus in USD 8B Deal

On 29 September 2025, Genmab A/S and Merus N.V. announced that they have entered into an agreement for Genmab to acquire all the shares of Merus… Read more here.


 

 

About Pearce IP

Pearce IP is a specialist firm offering intellectual property specialist lawyers and attorneys with a focus on the life sciences industries.  Pearce IP and its leaders are ranked in every notable legal directory for legal, patent and trade mark excellence, including: Chambers & Partners, Legal 500, IAM Patent 1000, IAM Strategy 300, MIP IP Stars, Doyles Guide, WTR 1000, Best Lawyers, WIPR Leaders, 5 Star IP Lawyers, among others.

In 2025, Pearce IP was recognised by Australasian Lawyer and New Zealand Lawyer’s 5 Star Employer of Choice, and is the “Standout Winner” for inclusion and culture for firms with less than 100 employees. Pearce IP was awarded “IP Team of the Year” by Lawyers Weekly at the 2021 Australian Law Awards. Pearce IP is recognised by Managing IP as the only leading ANZ IP firm with a female founder, and is certified by WEConnect International as women owned.

 

Naomi Pearce

Naomi Pearce

CEO, Executive Lawyer (AU, NZ), Patent Attorney (AU, NZ) & Trade Mark Attorney (AU)

Naomi is the founder of Pearce IP, and is one of Australia’s leading IP practitioners.   Naomi is a market leading, strategic, commercially astute, patent lawyer, patent attorney and trade mark attorney, with over 25 years’ experience, and a background in molecular biology/biochemistry.  Ranked in virtually every notable legal directory, highly regarded by peers and clients, with a background in molecular biology, Naomi is renown for her successful and elegant IP/legal strategies.

Among other awards, Naomi is ranked in Chambers, IAM Patent 1000, IAM Strategy 300, is a MIP “Patent Star”, and is recognised as a WIPR Leader for patents and trade marks. Naomi is the 2023 Lawyers Weekly “IP Partner of the Year”, the 2022 Lexology client choice award recipient for Life Sciences, the 2022 Asia Pacific Women in Business Law “Patent Lawyer of the Year” and the 2021 Lawyers Weekly Women in Law SME “Partner of the Year”.  Naomi is the founder of Pearce IP, which commenced in 2017 and won 2021 “IP Team of the Year” at the Australian Law Awards.

Chantal Savage

Chantal Savage

Special Counsel, Lawyer

Chantal is an intellectual property disputes lawyer with experience advising across the spectrum of IP rights, including patents, trade marks, copyright, plant breeder’s rights and trade secrets/confidential information. Recognised as a Rising Star in IP by the Legal 500 Asia Pacific (2021-2024), Chantal has previously worked for international and top tier law firms in Australia and the United Kingdom and now at Pearce IP.

With a science degree specialising in molecular biology and biochemistry, Chantal’s practice focuses particularly on complex, high-value, multi-jurisdictional patent infringement and revocation proceedings for clients in the life sciences sectors.

Nathan Kan

Nathan Kan

Lawyer

Nathan is a lawyer specialising in life sciences, providing legal advice and litigation support across intellectual property and commercial disputes. He is passionate about the intersection of law and science, and during his time with the Science and Technology Law Association at the University of Melbourne, he helped lead events, workshops and publications across STEM fields including life sciences, AI and digital transformation.

 

Regeneron & Bayer Fail in Bid to Prevent UK Launch of Aflibercept Biosimilars by Samsung Bioepis and Formycon/Klinge

On 8 October 2025, judgment was published in patent infringement proceedings brought by Regeneron/Bayer in the UK seeking to prevent Samsung Bioepis and Formycon/Klinge from launching biosimilars to Regeneron/Bayer’s Eylea® (aflibercept) in the UK after the November 2025 expiry of a supplementary protection certificate for the patent on aflibercept (EP 1 183 353).  Mr Justice Meade of the High Court of Justice of England and Wales found that Formycon/Klinge’s and Samsung Bioepis’ aflibercept biosimilars did not infringe either of the patents asserted by Regeneron (EP (UK) 2 364 691 and EP (UK) 2 944 306) and held that the ‘306 patent was invalid (for added matter).

The asserted ‘691 and ‘306 patents each relate to formulations of aflibercept for intravitreal use.  Neither Formycon/Klinge’s nor Samsung Bioepis’ products possess all the formulation features of the claims in that they use a different excipient from the one claimed and/or they omit one of the claimed excipients and/or they use a different amount of an excipient from that claimed in the patents.  Regeneron accepted that there was no literal infringement but argued that there was infringement by equivalence in each case.  The Court rejected this argument, holding that all allegations of infringement by equivalence failed.

The Court has scheduled a hearing on the form of orders to be made (unless the parties can agree) on 7 November 2025.  No appeal can be filed until after that time.

Subject to any successful appeal, the decision clears the way for a November 2025 launch of Formycon/Klinge’s aflibercept biosimilar, Ahzantive®/FYB203, which was approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA) in February 2025.  Samsung Bioepis’ Opuviz®/SB15 has not yet been approved in the UK, but was approved in Europe in November 2024.

Raising the Bar Too High: Dairy Substitute Patent Falls Short of Support and Sufficiency Requirements

 

Date of decision: 28 March 2025
Body:  Federal Court
Adjudicator: Justice Rofe

Introduction

Earlier this year, the Federal Court of Australia handed down judgment in proceedings between Perfect Day, Inc. and the Commissioner of Patents, in an appeal from an opposition decision concerning a patent application for dairy substitute food compositions.  Justice Rofe dismissed Perfect Day’s appeal and refused to allow the application to proceed to grant, finding that the claims failed to meet the heightened support and sufficiency requirements introduced under the ‘Raising the Bar’ amendments.

Background

Perfect Day was the applicant for patent AU2015305271 (the Application),  entitled ‘Compositions comprising a casein and methods of producing the same’.  The Application was directed to dairy substitutes that aim to replicate the characteristics of mammalian milk, based on the discovery that only a subset of components in the milk can be used to generate a composition that has similar characteristics, such as flavour, appearance, nutritional value, aroma, and mouthfeel.  The Application described various milk proteins, though most relevant to the Application were the casein proteins, α-lactalbumin (ALA) and β-lactoglobulin (BLG) proteins and their recombinant equivalents, rALA and rBLG, respectively.

The Application claimed an earliest priority date of 21 August 2014, and was assessed under the Patents Act 1990 following the ‘Raising the Bar’ amendments which introduced heightened requirements for support and sufficiency.  Fonterra Co-operative Group Ltd successfully opposed the Application before a delegate of the Commissioner of Patents in Fonterra Co-operative Group Ltd v Perfect Day, Inc. [2022] APO 59, delivered on 23 August 2022.  The Delegate found that the specification was directed to dairy substitute foods comprising casein proteins, not compositions with only rALA and rBLG as claimed, and so concluded that all claims lacked support and that the specification failed to disclose the invention clearly and completely enough for performance by a person skilled in the art.

Perfect Day appealed to the Federal Court in September 2022, and also filed two interlocutory applications to amend the Application, seeking to narrow claim 1 to a food composition suitable as a dairy substitute comprising rALA and rBLG and not casein.  Fonterra later withdrew as the respondent, with the Commissioner of Patents becoming a party to the proceeding pursuant to r 34.23(2) of the Federal Court Rules.

Key Issues

The appeal centred on two key requirements under the Patents Act 1990:

  1. Section 40(3): Whether the claims were supported by the specification; and
  2. Section 40(2)(a): Whether the specification disclosed the invention clearly enough and completely enough for performance by a person skilled in the art.

The Commissioner challenged claim 1 on both grounds.  Claim 1 read as follows:

A food composition, other than a cottage cheese or a hard cheese, that is suitable as a dairy substitute, said food composition comprising:

(i)    a recombinant β-lactoglobulin protein and a recombinant α-lactalbumin protein, wherein one or both of the recombinant β-lactoglobulin protein and the recombinant α-lactalbumin protein comprises a sequence that is at least 90% identical to the bovine protein amino acid sequence and has been produced by a fungal cell;

(ii)    one or more sweetening agents;

(iii)    ash; and

(iv)    optionally, one or more lipids,

wherein:

the food composition has one or more characteristics of a dairy food product selected from the group consisting of: taste, aroma, appearance, handling, mouthfeel, density, structure, texture, elasticity, springiness, coagulation, binding, leavening, aeration, foaming, creaminess, and emulsification; and the food composition does not comprise any other milk proteins than those in (i).

(Emphasis added – underlining/strikethrough denotes the proposed amendments)

On support, Justice Rofe had to determine whether the Application’s technical contribution to the art justified the broad scope of claim 1, which encompassed compositions with any combination of the 17 listed characteristics in claim 1 (such as taste, aroma, appearance…etc) (the Listed Characteristics), and whether the specification described the claimed invention being compositions containing only rALA and rBLG proteins without casein.

On sufficiency, Justice Rofe had to consider whether the specification provided adequate guidance for the skilled person to make the claimed compositions across their full scope in view of various alleged gaps in the Application’s teaching regarding fundamental aspects of formulating dairy products.

Consideration

Construction

An important threshold issue was the construction of claim 1, particularly the phrase “one or more” in relation to the Listed Characteristics.  Perfect Day contended that claim 1 covered compositions with only one characteristic, but not all or even a minimum number of Listed Characteristics, and substantiated this view by reference to infringement, arguing that the claim would be infringed if a product had one of the Listed Characteristics, even if it had more than one.  However, Justice Rofe accepted the Commissioner’s broader construction, finding that Claim 1 encompassed compositions with one, multiple, or all of the Listed Characteristics.

Support

The Commissioner argued that the specification was directed to casein-containing compositions that may further include other milk proteins, and methods of making the same, whereas claim 1 was directed to compositions with rALA and rBLG as the only milk proteins and which did not include casein, making them fundamentally different inventions.

Perfect Day responded that the invention, as narrowly claimed, was disclosed in the specification, relying on the following:

(a)  The addition of a consistory clause – “…other than a cottage cheese or hard cheese, that is suitable as a dairy substitute, said food composition…”; and

(b)  Selected references in the specification as being a disclosure of the ALA and BLG proteins being in a food composition independently of casein, such as: “also provided are kits that include: (a) a mixture of one or more milk proteins, one or more fats, and one or more flavour compounds; and (b) a mixture of ash and at least one sweetening agent”. Further, the Application stated that in some embodiments of the kits, “the one or more milk proteins are selected from the group of: β-casein, κ-casein, [ALA], [BLG] … and serum albumin

Justice Rofe found that the invention claimed was fundamentally different from the invention disclosed in the specification when read as a whole.  The specification described food compositions that included casein and may further include other milk proteins, whereas the claimed invention comprised rALA and rBLG as the only milk proteins and did not include casein (or any other milk proteins).  Critical to her Honour’s analysis was that, save for the consistory clause, and as accepted by Perfect Day’s expert witness, Professor Tong, there was no mention of a food composition suitable as a dairy substitute comprising BLG and ALA and no other milk proteins, nor any description of making such a composition.  Moreover, the specification positively stated that, if sufficient casein was not present, micelles would not form, leading to poor mouth feel in synthetic milk products as micelles were particularly important for the optimum behaviour of milk.

Her Honour also rejected Perfect Day’s reliance on selected phrases from the specification, finding that even the strongest reference – which described BLG and ALA as the primary component of “at least a part of the milk protein component or composition” – did not convey an “inferential disclosure of a composition comprising ALA and BLG and no other milk proteins”.  In the context of an extensive specification describing casein-containing compositions, her Honour stated that an absence of casein “would require express wording to that effect”.

The Commissioner also contended that that the technical contribution of the invention described in the specification did not support food compositions having more than one, or all of the Listed Characteristics.

In response, Perfect Day argued that the essence of the invention was not referrable to the combination of the Listed Characteristics, but was with respect to the development of a dairy substitute that used recombinant proteins without casein.  In view of this, Perfect Day contended that enabling one characteristic at a time was sufficient given the claim’s “one or more” language, and the resulting composition did not have to be a ‘good’ dairy substitute as long as the ‘important characteristic’ was replicated.

Justice Rofe agreed with the Commissioner’s position, finding that claim 1 encompassed “compositions which might have one of the Listed Characteristics, as well as compositions which have two or even all of the Listed Characteristics”.  Her Honour noted that Professor Tong’s evidence that recreating all the characteristics would be “tremendous” demonstrated that the scope of claim 1 exceeded the technical contribution provided by the specification as whole.  Although Professor Tong could make compositions with one characteristic “reminiscent” of dairy products, Justice Rofe found he was applying his own expertise rather than following the Application’s teachings, which failed to explain fundamental aspects such as whether post-translational modification caused rALA or rBLG to form micelles (critical for milk behaviour) or how to achieve coagulation with rennet in the absence of casein (necessary for cheese).  His evidence also revealed that different characteristics applied to different dairy products, further demonstrating that the broad scope of claim 1 could not be justified by the Application’s limited disclosure.  For these reasons, Justice Rofe concluded that the Application lacked support.

Sufficiency

The Commissioner’s arguments on sufficiency mirrored those made in respect of support, namely, that the invention claimed was different from that disclosed in the specification, and that the specification provided no meaningful assistance for producing the claimed products with combinations of Listed Characteristics, offering at best a ‘starting point’ that left the skilled person to rely on their common general knowledge alone.

Consistently with its position on support, Perfect Day argued that claim 1 only required that the claimed composition be “suitable as a dairy substitute” by possessing one Listed Characteristic, arguing that the sufficiency requirement should therefore not require more than enabling one characteristic at a time.  Perfect Day again relied on the consistory clause as sufficient disclosure and Professor Tong’s evidence that compositions with individual characteristics could be produced without undue burden.

In addition to the matters which her Honour had considered in the context of support, Justice Rofe noted that Professor Tong acknowledged that the Application did not disclose a formulation he could follow from start to finish and that his ‘starting point’ simply involved replacing casein with rALA and rBLG without being able to predict the resulting properties of the product.  Cross-examination of Professor Tong also revealed that many experiments, anywhere from “more than 10” and possibly within the realm of 100, might be required to produce a particular dairy substitute composition with the desired characteristic(s).

Critically, Justice Rofe found that the Application provided no guidance for making dairy substitute compositions with two or more of the Listed Characteristics, concluding that such work would require “an exercise of inventive skill or ingenuity or undue effort” rather than routine work by a skilled person.  Accordingly, her Honour found that claim 1 lacked sufficiency.

Outcome and Implications

Justice Rofe dismissed Perfect Day’s appeal, finding that claim 1 of the amended Application lacked both support and sufficiency and should not proceed to grant.

The decision provides important guidance on the heightened support and sufficiency requirements under the “Raising the Bar” amendments to the Patents Act.  Justice Rofe’s decision also illustrates the risks of claiming broad ranges of characteristics in complex technical fields, and reinforces that consistory clauses and vague references cannot cure fundamental disconnects between specifications and claims.

 

About Pearce IP

Pearce IP is a specialist firm offering intellectual property specialist lawyers and attorneys with a focus on the life sciences industries.  Pearce IP and its leaders are ranked in every notable legal directory for legal, patent and trade mark excellence, including: Chambers & Partners, Legal 500, IAM Patent 1000, IAM Strategy 300, MIP IP Stars, Doyles Guide, WTR 1000, Best Lawyers, WIPR Leaders, 5 Star IP Lawyers, among others.

In 2025, Pearce IP was recognised by Australasian Lawyer and New Zealand Lawyer’s 5 Star Employer of Choice, and is the “Standout Winner” for inclusion and culture for firms with less than 100 employees. Pearce IP was awarded “IP Team of the Year” by Lawyers Weekly at the 2021 Australian Law Awards. Pearce IP is recognised by Managing IP as the only leading ANZ IP firm with a female founder, and is certified by WEConnect International as women owned.

 

Naomi Pearce

Naomi Pearce

CEO, Executive Lawyer (AU, NZ), Patent Attorney (AU, NZ) & Trade Mark Attorney (AU)

Naomi is the founder of Pearce IP, and is one of Australia’s leading IP practitioners.   Naomi is a market leading, strategic, commercially astute, patent lawyer, patent attorney and trade mark attorney, with over 25 years’ experience, and a background in molecular biology/biochemistry.  Ranked in virtually every notable legal directory, highly regarded by peers and clients, with a background in molecular biology, Naomi is renown for her successful and elegant IP/legal strategies.

Among other awards, Naomi is ranked in Chambers, IAM Patent 1000, IAM Strategy 300, is a MIP “Patent Star”, and is recognised as a WIPR Leader for patents and trade marks. Naomi is the 2023 Lawyers Weekly “IP Partner of the Year”, the 2022 Lexology client choice award recipient for Life Sciences, the 2022 Asia Pacific Women in Business Law “Patent Lawyer of the Year” and the 2021 Lawyers Weekly Women in Law SME “Partner of the Year”.  Naomi is the founder of Pearce IP, which commenced in 2017 and won 2021 “IP Team of the Year” at the Australian Law Awards.

Helen Macpherson

Helen Macpherson

Executive, Lawyer (Head of Litigation –Australia)

Helen has over 25 years’ experience as an intellectual property specialist and is recognised as an industry leader. Helen advises on all forms of intellectual property including patents, plant breeder’s rights, trade marks, copyright and confidential information.

Throughout her career, Helen has maintained a strong focus on high-value patent mandates involving complex technologies. In these mandates, Helen has been able to draw upon her technical training in biochemistry and molecular biology, as well as her ability to up-skill swiftly in relation to diverse technologies. Helen’s patent work has encompassed the technical fields of inorganic, organic, physical and process chemistry, biochemistry, biotechnology (including genetics, molecular biology and virology) and physics.

Helen is a member of the Intellectual Property Committee of the Law Council of Australia, as well as a member of the Intellectual Property Society of Australia and New Zealand.

Nathan Kan

Nathan Kan

Lawyer

Nathan is a lawyer specialising in life sciences, providing legal advice and litigation support across intellectual property and commercial disputes. He is passionate about the intersection of law and science, and during his time with the Science and Technology Law Association at the University of Melbourne, he helped lead events, workshops and publications across STEM fields including life sciences, AI and digital transformation.

 

PTAB Invalidates 4 of Johns Hopkins’ US Pembrolizumab Patents in MSD IPRs

Between 18 and 23 September 2025, the US Patent Trial and Appeal Board (PTAB) issued final decisions invalidating Johns Hopkins University’s 11,339,219 (IPR2024-00625), 11,649,287 (IPR2024-00647), 11,629,187 (IPR2024-00649) and 11,634,491 (IPR2024-00650) in four inter partes review proceedings (IPRs) brought by MSD.  JHU subsequently filed an appeal in relation to Patent 11,649,287 (IPR2024-00647) on 7 October 2025.

The four JHU patents relate to the use of pembrolizumab in treating cancer patients with high mutational burdens, such as those found in microsatellite instability high (MSI) or DNA mismatch repair deficient cancer (dMMR).  The PTAB found that the patents were invalid for lack of novelty and/or obviousness based on prior art including a record of a JHU phase 2 clinical trial of Keytruda® (pembrolizumab) in MSI/dMMR cancer.

The four IPRs are a subset of nine IPRs filed by MSD against JHU patents in 2023 – 2024.  One of the IPRs had previously been determined in June 2025, finding US 11,591, 393 invalid.  The remaining four IPRs remain pending:

In November 2022, MSD filed a complaint in the United States District Court (District of Maryland) against JHU seeking declarations of breach of contract, non-infringement and promissory estoppel.  Based on the complaint, the dispute arose out of a contract between MSD and JHU to design and conduct a clinical trial on administration regimes for Keytruda® (pembrolizumab) in cancer patients with certain genetic biomarkers.  JHU filed a counter-claim on 12 April 2023, including alleging infringement of each of the patents subject to the IPR proceedings referred to above.  The US Court proceeding has been stayed pending the outcome of the IPRs.  No trial date has been scheduled.

New Indication Alert: J&J’s Simponi® (Golimumab) FDA-Approved for Paediatric UC

On 7 October 2025, Johnson & Johnson announced that the FDA has approved Simponi® (golimumab) for treating children living with moderately to severely active ulcerative colitis (UC), weighing at least 15 kg.  The FDA approval follows J&J’s submission of the sBLA for this indication in December 2024.

Simponi® has previously been FDA approved for adults with moderately to severely active UC, moderate to severe rheumatoid arthritis, active psoriatic arthritis and active ankylosing spondylitis.

The first golimumab biosimilar to be approved worldwide was Alvotech/Fuji Pharma’s AVT05, which received approval in Japan in September 2025.  Earlier in September 2025, Alvotech/Advanz’s Gobivaz® received a positive opinion from the European Medicine Agency’s CHMP, after the European MAA for that product was the first golimumab MAA to be accepted anywhere in the world (November 2024).  Alvotech/Teva’s Biologics Licence Application (BLA) for AVT05 was accepted by the FDA in January 2025, with approval expected in Q4/2025.

Bio-Thera/STADA’s MAA for the golimumab biosimilar BAT2506 was accepted by the EMA in February 2025, while Bio-Thera/Accord’s BLA for BAT2506 was accepted for FDA review in July 2025.

Japan Grows Domestic Biosimilar Supply System

On 6 October 2025, Alfresa Holdings announced that it has entered into agreements with two other Japanese companies, Kidswell Bio Corporation and Chiome Bioscience Inc., to jointly develop biosimilars for unnamed specified products in Japan.

The agreement follows the selection of the three companies by the Japanese Ministry of Health, Labour and Welfare (MHLW) to establish a domestic manufacturing facility for biosimilars.  The MHLW initiative is part of a program which aims to ensure that biosimilars account for more than 80% of total prescriptions in Japan for at least 60% of all eligible active ingredients by the end of FY29.

The manufacturing processes for the biosimilars subject to the agreements are expected to be transferred to the domestic manufacturing facility established under the MHLW’s program, for commercial production.

The companies intend to leverage their respective expertise (Alfresa’s nationwide pharmaceutical distribution network and manufacturing capabilities, Kidswell’s experience in development and stable supply of multiple biosimilars and Chiome’s expertise in antibody drug R&D), supported by the Taiwanese CDMO Mycenax Biotech, to work towards developing a stable Japanese biosimilar supply system.

EMA Accepts Alvotech’s Marketing Authorisation Application for Biosimilar Omalizumab

On 6 October 2025, Alvotech announced that the European Medicines Agency (EMA) has accepted its marketing authorisation application (MAA) for AVT23, biosimilar to Genentech/Novartis’ Xolair® (omalizumab).

AVT23 (also known as ADL-018) was developed by Alvotech in collaboration with Kashiv Biosciences and is the subject of an October 2023 licensing agreement under which Advanz Pharma has exclusive commercialisation rights for the European Economic Area (European Union, Norway, Iceland and Lichtenstein), the UK, Switzerland, Canada, Australia and New Zealand.  A marketing application for AVT23 was accepted by the UK’s MHRA in March 2025.

Celltrion has already commenced the European launch of its omalizumab biosimilar, Omlyclo®, beginning in Norway in September 2025.  Omlyclo® is approved in the EU (May 2024), Korea (June 2024), Australia (November 2024), Canada (December 2024), the US (March 2025) and New Zealand (April 2025).  It has been the subject of patent infringement actions in at least the UK and Europe.  Omalizumab biosimilars are also under development by Aurobindo, Teva and Glenmark.

Celltrion & Hikma Expand MENA Partnership to Include 6 Additional Biosimilars

On 6 October 2025, Hikma Pharmaceuticals and Celltrion Inc, announced that they have entered exclusive licensing agreements for 6 biosimilars, across the Middle East and North Africa (MENA) region.  The identities of the biosimilars have not yet been disclosed but they are said to treat “key therapeutic areas”, including allergic diseases, ophthalmology, skeletal-related disorders, immune diseases and oncology.

Under the agreements, Hikma holds the exclusive commercialisation rights across all MENA markets, while Celltrion is responsible for the development, manufacturing and supply of the biosimilars.

Hikma and Celltrion have previously partnered in relation to the commercialisation of multiple biosimilars in MENA, including a January 2023 deal regarding Vegzelma® (CT-P16, biosimilar bevacizumab), 2022 deals for CT-P43 (biosimilar ustekinumab) and Yuflyma™ (biosimilar adalimumab), and agreements for Truxima® (biosimilar rituximab), Remsima®/Remsima® SC (biosimilar infliximab) and Herzuma® (biosimilar trastuzumab).

There have been a number of recent announcements regarding commercialisation of biosimilars in MENA, with deals for Polpharma & MS Pharma in September 2025 (biosimilar guselkumab (PB019), ocrelizumab (PB018) and vedolizumab (PB016)), Bio-Thera & Jamjoom Pharma in September 2025 (biosimilar secukinumab (BAT2306)), and Kashiv & MS Pharma in August 2025 (biosimilar omalizumab (ADL-018)).

CSPC Pharmaceutical’s Biosimilar Ustekinumab Ph 3 Results

On 3 October 2025, Pharmacy Times reported that CSPC Pharmaceutical Group’s SYSA1902 has been shown in a phase 3 study to be clinically equivalent to its reference product, Janssen’s Stelara® (ustekinumab) for the treatment of moderate to severe plaque psoriasis.

The results of the phase 3 study were published in the Journal of the American Academy of Dermatology in April 2025.  The results are likely to form the basis for an FDA approval application.

The phase 3 study follows CSPC’s November 2024 announcement that its biologic license application for ustekinumab was accepted by the People’s Republic of China’s National Medical Products Administration.  CSPC’s ustekinumab biosimilar was developed by related company CSPC Megalith Biopharmaceuticals.

Samsung Bioepis Successfully Opposes Grant of Janssen’s AU Ustekinumab Patent Application

On 3 October 2025, IP Australia delivered its decision in Samsung Bioepis’ opposition to the grant of Janssen’s AU2019346134 relating to a method of treating ulcerative colitis with Stelara® (ustekinumab).  IP Australia ruled that the patent application was invalid for lack of novelty and inventive step in light of prior art, including a clinical trial record.  Samsung Bioepis was unsuccessful on its third opposition ground, lack of support.

Janssen now has until 24 October 2025 by which to appeal the opposition decision to the Federal Court of Australia.  IP Australia has also given Janssen until 3 December 2025 to propose amendments to seek to overcome the deficiencies in the claims.

The IP Australia decision marks yet another success for Samsung Bioepis in its Australian litigation against Janssen regarding Janssen’s Australian ustekinumab patent portfolio for the treatment of ulcerative colitis.  On 9 June 2025, the Federal Court of Australia ordered that three Janssen Biotech innovation patents be revoked (AU2024100006, AU2024100007 and AU2024100016).  In an earlier victory for Samsung Bioepis, Janssen surrendered two innovation patents (AU 2023100041 and 2023100042).  The Janssen innovation patents all related to a method of treating ulcerative colitis with ustekinumab.

Samsung Bioepis’ Epyztek® (ustekinumab) was approved in Australia in October 2024 and was recommended for PBS-listing at PBAC’s March 2025 meeting, but the current status of the application is recorded as “inactive”.

The Australian ustekinumab legal actions are part of a global suite of actions between Samsung Bioepis and Janssen, with Samsung Bioepis having claimed victory in other key jurisdictions including:

Celltrion Launches IV Tocilizumab Biosimilar in US

On 3 October 2025, Celltrion announced that it has launched its intravenous formulation of Avtozma®/CT-P47, biosimilar to Roche’s Actemra® (tocilizumab), in the United States.  Avtozma® IV is indicated for all reference indications, with the FDA approving an indication extension for the treatment of cytokine release syndrome (CRS) in August 2025.

Avtozma® is the third tocilizumab biosimilar approved in the US (January 2025).  Biogen/Bio-Thera’s Tofidence®/BAT1806 (tocilizumab-bavi) was the first US approved tocilizumab biosimilar (IV formulation, September 2023; launched May 2024), followed by Fresenius Kabi’s Tyenne® (tocilizumab-aazg) (SC formulation, March 2024; IV formulation launched April 2024SC formulation launched July 2024).

In February 2025, Avtozma® became the third tocilizumab biosimilar approved in the EU, following Fresenius Kabi’s Tyenne®, in both IV and SC forms in November 2023, and Biogen’s IV Tofidence® in June 2024.

Celltrion’s Avtozma® is the first and only tocilizumab biosimilar to be approved in Australia (May 2025) and will be considered for PBS listing at PBAC’s November 2025 meeting.

Formycon/Klinge/Valorum Set for Q4/2026 Biosimilar Aflibercept US Launch Following Regeneron Settlement

On 2 October 2025, Formycon announced that it and its licence partners, Klinge Biopharma and Valorum Biologics, have entered a settlement and licence agreement with Regeneron to resolve all US patent disputes relating to FYB203/Ahzantive®, biosimilar to Regeneron’s Eylea® (aflibercept).  Under the terms of the agreement, Valorum may launch Ahzantive® in the US in Q4/2026, or earlier under certain undisclosed circumstances.

FYB203 was approved in the US in June 2024 and had been subject to a preliminary injunction granted by the US District Court for the Northern District of West Virginia in June 2024, resulting from a patent infringement proceeding brought by Regeneron in November 2023.  The injunction was upheld on appeal in January 2025 but has now been vacated as a result of the parties’ settlement.

Sandoz has also recently (in September 2025) settled BPCIA aflibercept litigation with Regeneron, with a US launch date for Sandoz’s Enzeevu® set for Q4/2026 (or earlier under certain undisclosed circumstances).

The only aflibercept biosimilar to have launched in the US to date is Amgen’s Pavblu™, which launched in October 2024 following the US Court of Appeals for the Federal Circuit’s denial of Regeneron’s application for an injunction in relation to the biosimilar.  Regeneron has since commenced new BPCIA litigation against Amgen for Pavblu™ (June 2025), which remains pending.

Klinge, Formycon’s exclusive global licensee of FYB203, entered an exclusive licence agreement with Valorum in June 2025 for the commercialisation of FYB203 in the US and Canada.  Under the agreement, Klinge receives royalties on net sales and is eligible to receive upfront and milestone payments, with Formycon receiving a single to low double-digit percentage of those payment streams.  Formycon will additionally receive service payments and a volume-based profit component for organising the commercial market supply on behalf of Klinge.

The dispute between Regeneron/Bayer and Formycon in relation to FYB203 is not limited to the US, with legal proceedings in the US, UK, Italy, Belgium, the Netherlands, and France.  On 25 September 2025, the Munich Regional Court granted Regeneron and Bayer a cross-border preliminary injunction (PI) preventing Formycon from launching FYB203 in a number of European countries, including Germany.  The PI was based on a finding of infringement by equivalence of Regeneron’s formulation patent, EP 2 364 691.

 

Biocon Launches Denosumab Biosimilars in US Following Amgen Settlement

On 1 October 2025, Biocon announced that it has entered into a settlement and licence agreement with Amgen that resolves pending BPCIA patent litigation and permits Biocon’s 1 October 2025 US launch of Bosaya™ and Aukelso™ (denosumab-kyqq), biosimilars to Amgen’s Prolia® and Xgeva® respectively.

Amgen had filed the BPCIA litigation against Biocon on 30 June 2025 in the US District Court for the District of Massachusetts, Eastern Division, asserting infringement of 34 US patents covering denosumab, pharmaceutical compositions of denosumab, methods of manufacturing therapeutic proteins, like denosumab, and denosumab products.

The proceeding against Biocon was one of a number of proceedings that Amgen commenced in the US in relation to denosumab biosimilars, six of which have now settled (including the Biocon settlement):

Amgen still has pending US denosumab litigation against Hikma/Gedeon Richter and Shanghai Henlius/Organon, which have had denosumab biosimilar applications accepted for review by the FDA.

Bosaya™ and Aukelso™ received FDA approval in September 2025 and were granted provisional interchangeability designation for all approved indications.  They were the sixth pair of denosumab biosimilars to be approved in the US, following Sandoz’s Jubbonti® and Wyost® (approved March 2024, launched June 2025), Samsung Bioepis’ Obodence™ and Xbryk™ (approved February 2025, not yet launched), Celltrion’s Stoboclo® and Osenvelt® (approved March 2025, launched July 2025), Fresenius Kabi’s Conexxence® and Bomyntra® (approved March 2025, launched July 2025), and Shanghai Henlius/Organon’s Bildyos® and Bilprevda® (approved September 2025, not yet launched).  Richter/Hikma’s Enoby™ and Xtrenbo™ (denosumab qbde) were subsequently approved later in September 2025.

BioBlast® Editor and Contributing Author

Naomi Pearce & Emily Bristow

Naomi Pearce & Emily Bristow

Editor: Naomi Pearce, Executive Lawyer, Patent Attorney & Trade Mark Attorney
Contributing Author: Emily Bristow, Law Graduate

Get our Pearce IP Blogs & BioBlast® sent directly to your inbox

Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.